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Abstract
VIM-6, previously reported in two strains from Singapore recov-
ered in 2000, was detected in 16 isolates collected in 2006 in
India (12 isolates), Indonesia (two), Korea and the Philippines
(one each). High genetic variability was observed among VIM-6-
producing isolates (12 ribotypes and 11 pulsed-ﬁeld gel electro-
phoresis types), but clones were observed in India and Indone-
sia; blaVIM-6-carrying integrons of 3.9 kb and 5 kb were detected,
and two of ﬁve Indian hospitals yielded isolates with both integ-
rons. These two integrons, blaVIM-6 was located in the ﬁrst posi-
tion, followed by blaOXA-10 and aacA4. The 5-kb integrons also
harboured aadA1 and a 331-bp open reading frame encoding a
putative efﬂux pump.
Keywords: Asia-Paciﬁc, metallo-b-lactamases, Pseudomonas aeru-
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Acquired metallo-b-lactamase (MBL)-producing isolates have
been increasingly reported in the Asia-Paciﬁc (APAC) region.
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Several MBL types were found in Korea (IMP-1, IMP-8, VIM-
2, and SIM-1), China (IMP-4, IMP-9, and VIM-2) and Taiwan
(IMP-8, VIM-2, and VIM-3), among other countries from that
region [1,2]. A new VIM-type enzyme was identiﬁed in two
Pseudomonas putida isolates recovered in Singapore in 2000
[3]. This enzyme, named VIM-6, showed only two amino acid
differences from VIM-2, which is probably its genetic ances-
tor. VIM-6 has not been reported in any other geographical
location, and its description was succinct, focusing on the
clinical ﬁndings.
In this study, we report 16 blaVIM-6-carrying Pseudomonas
aeruginosa isolates from four countries in the APAC region,
and their genetic context.
A total of 719 P. aeruginosa isolates were consecutively
collected from bloodstream, respiratory tracts and skin and
skin structure infections in 57 hospitals located in the APAC
region during the SENTRY Antimicrobial Surveillance Pro-
gram (2006). Isolates were susceptibility-tested by CLSI
broth microdilution [4,5]. Among those strains, 196 (27.3%)
were non-susceptible (MIC of ‡8 mg/L) to imipenem and/or
meropenem and were tested using generic primers designed
to align multiple variants of IMP, VIM and other MBL genes
in a multiplex PCR approach [6]. All amplicons were
sequenced on both strands and analysed. The blaVIM-6 gene
was detected in 16 (8.1%) isolates recovered in India (12 iso-
lates), Indonesia (two), Korea (one), and the Philippines
(one; Table 1). All isolates were resistant to three or more
classes of antipseudomonal agents. Two isolates from India
were susceptible to ﬂuoroquinolones (ciproﬂoxacin MIC of
0.12 and 0.5 mg/L), whereas polymyxin B and colistin
remained active against all strains (MIC of 0.5–1 mg/L).
Primers annealing in the two conserved regions (CS) of
class 1 integrons [7] were used in combination with MBL
primers to determine the size of the integron structure. The
blaVIM-6 gene was carried as a gene cassette in the ﬁrst posi-
tion of 3.9-kb and 5-kb class 1 integrons (Table 1). Ampli-
cons generated with blaVIM primers anchored in the 3¢CS
were digested with DraI and XbaI in separate reactions. In-
tegrons of the same size generated identical restriction frag-
ment length polymorphism patterns, indicating a similar
content and arrangement. Sequencing showed that the 3.9-
kb integrons carried blaVIM-6, blaOXA-10 and aacA4 followed
by qacED1/sul1 in the 3¢CS (Fig. 1). The 5-kb integrons pos-
sessed the same gene content but two additional gene cas-
settes: a 331-bp open reading frame (ORF) and aadA1
upstream of the 3¢CS (Fig. 1). The 5-kb integrons found in
this study appear to be identical to the blaVIM-6 integron car-
ried by the isolate found in Singapore, which has been
deposited in GenBank (no. EF522838) but not yet described.
In two isolates, the 3¢CS could not be ampliﬁed with several
different primers annealing in different structures found in
the 3¢-end of class 1 integrons. However, primers annealing
in aacA4 and aadA1 showed that these genetic structures
were similar to the other blaVIM-6-carrying integrons
described here (Table 1).
The putative protein encoded by the 331-bp ORF carried
in the 5-kb integrons showed 78% similarity with the efﬂux
pump QACED1, which provides resistance to quaternary
ammonium compounds. The orf was cloned into pPCRScript-
Cam SK+ (Stratagene Cloning Systems, La Jolla, CA, USA),
and recombinant strains were tested by MIC methods [4]
for several clinically available antimicrobial agents and other
TABLE 1. Characteristics of 16 blaVIM-6-carrying Pseudomonas aeruginosa isolates obtained in 2006 in the Asia-Paciﬁc (APAC)
region
Isolate Country Hospital Source Ribotypea PFGE pattern Integron size
225-22-D Korea A Abscess 1034-2 A 5 kb-likeb
228-23-D Philippines B Skin and soft tissue 35-7 B 3.9 kb-likeb
241-09-D Indonesia C Wound 566-6 C 5 kb
241-73.2-D Indonesia C Abscess 566-6 C1 5 kb
244-07-D India D Skin and soft tissue 566-2 D 3.9 kb
244-10-D India D Wound 347-6 E 5 kb
244-18-C India D Tracheal aspirate 347-8 E1 5 kb
244-24-D India D Tissue 352-2 E 5 kb
244-29-D India D Unknown 352-2 E 5 kb
247-03-D India E Wound 348-6 F 5 kb
247-06-D India E Wound 348-6 F 5 kb
248-11-A India F Blood culture 45-6 G 3.9 kb
248-26-C India F Unknown 45-6 H 3.9 kb
248-77-C India F Unknown 114-4 I 5 kb
252-05-C India G Sputum 147-6 J 3.9 kb
252-09-C India G Endotracheal tube 134-4 K 3.9 kb
PFGE, pulsed-ﬁeld gel electrophoresis.
aIsolates were considered to be grouped in the same ribotype if the similarity coefﬁcient was ‡0.93. Ribotypes were named according to the batch (ﬁrst three digits) and
sample position (last single digit) of the ﬁrst isolate identiﬁed with that pattern.
bThe same gene cassette arrangement was observed, but the 3¢CS could not be ampliﬁed.
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antibacterial compounds, such as surfactants and detergents
(Brij58, deoxicolate Tween-80, chlorhexidine, benzalconium,
sodium dodecylsulphate and sarkosyl), dyes (ethidium bro-
mide and crystal violet), and heavy metals (cadmium, lithium,
nickel and chromium). The results showed no consistent
differences in the MIC values for the Escherichia coli strains
harbouring the plasmid containing the 331-bp ORF or the
plasmid without the insert. The expression of orf was
conﬁrmed in the clinical isolate and in the recombinant
colonies by RT-PCR (OneStep RT-PCR kit; Qiagen, Hilden,
Germany) in RNA preparations (RNeasy Mini kit; Qiagen)
previously treated with RNase-free DNase (Promega, Madi-
son, WI, USA). Although this gene did not confer a pheno-
type of resistance to the compounds tested, this putative
efﬂux pump could still play a role in the selection of strains
harbouring these mobile elements.
MBL-producing isolates were ribotyped using PvuII in the
Riboprinter Microbial Characterization System (Qualicon,
Wilmington, DE, USA). Isolates were also evaluated using
pulsed-ﬁeld gel electrophoresis (PFGE), as previously
described [8]. Isolates carrying blaVIM-6 were clustered in 12
ribotypes and 11 PFGE patterns (Table 1). Three clones of
two isolates each were identiﬁed in India by ribotyping, but
PFGE showed that isolates from one suspected clone were
not related. Whereas ribotyping identiﬁed a clone with two
isolates in one Indian hospital, PFGE demonstrated that
four isolates from the same hospital were genetically
related (clone E/E1). The two other clonal strains from
India and the two isolates from Indonesia were found
to be genetically related by both epidemiological methods.
The other ﬁve strains, including the strains found in Korea
and the Philippines, showed unique ribotypes and PFGE
patterns.
Six isolates harboured the 3.9-kb blaVIM-6-carrying integrons,
and all but one isolate were found in three Indian medical sites
(Table 1). The remaining organism carrying a 3.9-kb integron
was recovered in the Philippines, and this integron lacked the
conventional 3¢CS of class 1 integrons. All isolates were geneti-
cally distinct according to PFGE analysis; nonetheless, two
isolates from one hospital were clustered in the same ribotype,
showing genetic relatedness. Less genetic variability was noted
in the isolates carrying 5-kb integrons (three clones).
Plasmid DNA from the VIM-6-producing strains was
extracted using the Plasmid DNA Midi Kit (Qiagen) and
resolved on agarose gels. E. coli NTCC 50192 was used as a
molecular weight marker. Transfer of plasmid DNA to a
nylon membrane was performed by Southern blot as
described previously [9]. The blaVIM-6 probe generated by
PCR was labelled and membranes were hybridized using the
non-radioactive DIG high Prime DNA labelling and detection
kit (Roche Diagnostics GmbH, Mannheim, Germany). All iso-
lates showed at least one plasmid band, and the blaVIM-6
probe hybridization demonstrated that this MBL gene was
carried by plasmids of approximately 35 kb in all isolates,
including isolates carrying different blaVIM-6 integrons. This
suggests that these plasmids continually undergo genetic
events, such as rearrangements, incisions, and excisions. Our
results show that a genetic structure carrying blaVIM-6 is
probably responsible for the dissemination of this MBL gene
in the four APAC countries; however, we also observed clo-
nal spread of VIM-6-producing strains in speciﬁc hospitals.
The blaVIM-6 gene was initially reported from two P. putida
clinical isolates recovered in Singapore, but the context of this
gene has not been described [3]. In this study, this MBL gene
was found in four more countries of the APAC region, includ-
ing Indonesia and the Philippines, where MBLs have not previ-
ously been reported. The spread and high genetic diversity
observed among blaVIM-6-harbouring isolates can be attributed
to a promiscuous mobile structure that carries this MBL gene.
Nucleotide Sequence Accession Number
The nucleotide sequence of the 3.9-kb integron carrying





intI1 blaVIM-6 blaOXA-10 aacA4
5´CS 
331 bp ORF aadA1
FIG. 1. Schematic representation of blaVIM-6-
carrying integrons detected in carbapenem-
resistant Pseudomonas aeruginosa isolates from
the Asia-Paciﬁc region. The 5-kb integrons
possessed a 331-bp open reading frame (ORF)
and aadA1 that were not present in 3.9-kb
structures.
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Abstract
From 2002 to 2006, 35 of 73 multidrug-resistant Pseudomonas
aeruginosa isolates from different wards at Charles Nicolle hospi-
tal of Tunis were positive for class B carbapenemase (using the
imipenem–EDTA test), owing to a blaVIM-2 gene cassette in a
class 1 integron. Twenty-three isolates additionally produced the
extended-spectrum b-lactamase SHV2a. DNA sequences imme-
diately surrounding blaSHV2a shared extensive identity with a
Klebsiella pneumoniae plasmid sequence. Despite belonging to the
same chromosomal type, as shown by pulsed-ﬁeld gel electro-
phoresis (PFGE), the VIM-2 producing P. aeruginosa isolates
prevalent at Charles Nicolle hospital displayed a diversity of
VIM-2-carrying integrons.
Keywords: Carbapenem resistance, Pseudomonas aeruginosa,
SHV-2a extended-spectrum b-lactamase, VIM-2 metallo-b-
lactamase
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Carbapenems are among the drugs of choice for the
treatment of infections due to multidrug-resistant (MDR)
Pseudomonas aeruginosa. However, their efﬁcacy is being
increasingly compromised by the emergence of P. aeruginosa
strains producing metallo-b-lactamases (MBLs) [1], which are
implicated in large outbreaks, as described in Greece, Italy,
Canada, Korea and Kenya [2–6]. We report the ﬁrst molec-
ular characterization of Tunisian MBL-producing P. aeruginosa
isolates, some of which were also extended-spectrum
b-lactamase producers.
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